What is Osler Diagnostics?
Osler Diagnostics is at the forefront of revolutionizing healthcare diagnostics with its portable, low-cost, and user-friendly technology. The company's flagship product, the Osler Origin, is engineered to consolidate multiple testing systems onto a single instrument, offering a comprehensive test menu suitable for diverse healthcare settings. This approach aims to democratize access to high-performance diagnostic testing, making it available "anywhere, anytime." The company's strategic focus on accessibility and accuracy positions it to transform global healthcare delivery, serving critical needs in emergency departments, doctors' offices, and retail pharmacies.
How much funding has Osler Diagnostics raised?
Osler Diagnostics has raised a total of $85M across 1 funding round:
Series C
$85M
Series C (2022): $85M with participation from M&G Investments, Lansdowne Partners, and Oxford Sciences Enterprises
Key Investors in Osler Diagnostics
M&G Investments
M&G Investments is a global asset manager providing a range of investment solutions. Their participation suggests a focus on companies with strong growth potential and robust financial strategies.
Lansdowne Partners
Founded in 1998 and headquartered in London, UK, Lansdowne Partners was established with the objective of building a leading investment management partnership focused on delivering superior long-term investment returns and exceptional client service. Their involvement indicates a belief in Osler Diagnostics' long-term value proposition.
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent, billion-pound investment company created in 2015 to found, fund and build transformational businesses via the company's unique partnership with the University of Oxford, the worlds #1 research university. Their investment highlights a commitment to cutting-edge scientific innovation.
What's next for Osler Diagnostics?
The substantial enterprise-level financing Osler Diagnostics has garnered, particularly the recent Series C round, indicates a strong market validation and positions the company for accelerated growth and market penetration. This capital injection is expected to fuel further research and development, enhance manufacturing capabilities, and expand its commercial reach. The strategic backing from prominent investors suggests a clear pathway towards achieving its mission of making advanced diagnostics universally accessible, potentially leading to significant advancements in early disease detection and patient management worldwide.
See full Osler Diagnostics company page
